Endomatrix, developer of a patented Endothelial Dysfunction Therapy (EDT) focused on treating the root cause of cardiovascular disease, has announced the signing of agreements for Capsugel to both develop and subsequently manufacture its first product, Provasca.
Provasca is a proprietary and patented nutraceutical product designed to address endothelial dysfunction - which affects the walls of arteries and can lead to inflammation of the arteries and supports cholesterol accumulation, both known causes of cardiovascular disease.
"Developing and manufacturing Provasca in a proprietary, state-of-the-art oral dosage form, the Licap from Capsugel, is an integral part of our strategy, and will allow us to get our breakthrough Endothelial Dysfunction Therapy (EDT) into the hands of consumers by the end of this year," stated Bruce Bouche, Endomatrix's vice president, global nutraceuticals.
"Having Provasca manufactured by Capsugel, not only provides our customers with the highest quality product, but also provides additional patent protection for Provasca," he continued.
Santa Rosa, California-based Endomatrix says Provasca is the first in a line of planned products, all of which will be based on the company's patented EDT.For further information contact Glenn Foley.